# US 5,833,989 A · Soluble CR1 derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,833,989 A
- Document ID: US5833989A
- Status: Granted
- Kind: A
- Application number: 08/356,361
- Filed: 1995-03-07
- Granted: 1998-11-10
- Earliest claimed: 1992-06-24
- Assignees: AdProTech Limited
- Inventors: Danuta Ewa Irena Mossakowska; Ian Dodd; Anne Mary Freeman; Richard Anthony Godwin Smith
- Web page: https://patentgrep.com/patent/US5833989A

## CPC

- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A soluble polypeptide comprising, in sequence, one to four short consensus repeats (SCR) selected from SCR 1, 2, 3 and 4 of long homologous repeat A (LHR-A) as the only structurally and functionally intact SCR domains of CR1 and including at least SCR3.

## Claims

### Claim 1

A soluble polypeptide comprising no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4.

### Claim 2

A soluble polypeptide comprising no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3.

### Claim 3

A soluble polypeptide that can inhibit complement activation and that comprises no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the soluble peptide is obtainable by
expressing in a host cell a DNA molecule encoding the soluble polypeptide to produce the soluble polypeptide, wherein the DNA molecule encodes SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4; and
harvesting the soluble polypeptide.

### Claim 4

A soluble polypeptide that can inhibit complement activation and that comprises no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the soluble peptide is obtainable by
expressing in a host cell a DNA molecule encoding SCR3 to produce the soluble polypeptide; and
harvesting the soluble polypeptide.

### Claim 5 (depends on 3)

A soluble polypeptide according to claim 3, wherein the host cell is a bacterium.

### Claim 6 (depends on 4)

A soluble polypeptide according to claim 4, wherein the host cell is a bacterium.

### Claim 7 (depends on 1)

A soluble polypeptide according to claim 1, wherein the polypeptide comprises three SCRs.

### Claim 8 (depends on 3)

A soluble polypeptide according to claim 3, wherein the polypeptide comprises three SCRs.

### Claim 9

A pharmaceutical composition for inhibiting complement activation, comprising a soluble polypeptide comprising no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4.

### Claim 10

A pharmaceutical composition for inhibiting complement activation, comprising a soluble polypeptide comprising no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3.

### Claim 11

A pharmaceutical composition for inhibiting complement activation, comprising a soluble polypeptide comprising no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the soluble polypeptide is obtainable by
expressing in a host cell a DNA molecule encoding SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4 in order to produce the soluble protein; and
harvesting the soluble polypeptide.

### Claim 12

A pharmaceutical composition for inhibiting complement activation comprising a soluble polypeptide comprising no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the soluble polypeptide is obtainable by
expressing in a host cell a DNA molecule encoding SCR3 in order to produce the soluble polypeptide; and
harvesting the soluble polypeptide.

### Claim 13 (depends on 11)

A pharmaceutical composition according to claim 11, wherein the host cell is a bacterium.

### Claim 14 (depends on 12)

A pharmaceutical composition according to claim 12, wherein the host cell is a bacterium.

### Claim 15

A method of treating a patient in need of inhibition of complement activation, comprising
administering to the patient a soluble polypeptide comprising no more than three short consensus repeats (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3 and at least one repeat selected from the group consisting of SCR1, SCR2, and SCR4.

### Claim 16

A method of treating a patient in need of inhibition of complement activation, comprising
administering to the patient a soluble polypeptide comprising no more than one short consensus repeat (SCR) of long homologous repeat A of Complement Receptor 1, wherein the polypeptide comprises SCR3.